Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • News & Featured Stories
  • Media
  • Careers
  • Contact Us
  • Our Science

    Sub Menu 1

    • Pfizer in the UK
      • Our History
      • Pharmaceutical Sciences
      • Devices Centre of Excellence
      • Global Regulatory Affairs
      • Material Characterisation Team
      • Anti-Counterfeit Laboratory
    • Our Therapy Areas
      • Anti-Infectives
      • Inflammation and Immunology
      • Internal Medicine
      • Oncology
      • Rare Disease
      • Vaccines

    Sub Menu 2

    • Developing New Medicines
      • Clinical Trials
      • Pipeline
    • Research partnerships
      • ADDoPT
      • Innovative Target Exploration Network (ITEN)
      • INSPIRE Programme
      • Medical Research Council Collaboration
      • The Stratified Medicine Programme
      • Partnership with Regeneron for UK Biobank exome sequencing
    • Breakthroughs that change patients’ lives
    Hot Topic

    Re-shaping Cancer

    Re-shaping cancer
  • Products

    Sub Menu 4

    • Prescription medicines

    Sub Menu 5

    • Safety of Medicines
      • Medicines Regulation
      • Reporting Side Effects
      • Counterfeit Medicines
    Hot Topic

    Vaccines partnerships

    Vaccines partnerships
  • Responsibility

    Sub Menu 7

    • Transparency
      • HCP & HCO Annual Disclosure Reports
      • Healthcare Organisation Grants
      • Research and Development Funding
      • Patient Organisation Funding and Support
    • Codes of Conduct
      • Gender Pay Gap Report
      • Section 172 Statements
      • Pfizer UK Modern Slavery Statement
      • Pfizer UK Tax Strategy

    Sub Menu 8

    • Environmental Sustainability
      • Climate Action
      • Global Actions
      • Our Partnerships & Commitments
      • Sustainable Medicines
      • UK Actions
    • Insurance Details
    • Animal Welfare
    Hot Topic

    Putting Patients First

    Putting Patients First
  • UK Society

    Sub Menu 10

    • Social Investment
      • Volunteering and Fundraising
      • Medicines Donations
    • Raising Public Awareness
      • Change the Course
      • Pfizer Sponsors Science Museum Group's 'Cancer Revolution' Exhibition
      • Pfizer Sponsors the Superhero Series
      • Pfizer sponsors Science Museum exhibition 'Superbugs'
      • Pfizer at the British Science Festival
      • Turning Heads at Westminster

    Sub Menu 11

    • Science Education
      • Developing Science Talent
      • 'Superbugs Join The Fight' School Programme
      • Online Learning
        • Student Education Area
        • Teacher Resources
      • Community Lab
      • Career Talks
      • Lab in a Box
    • Pfizer Worldwide
      • Global Health Fellows
      • Global Aid and Emergency Relief
      • International Trachoma Initiative
    Hot Topic

    'Superbugs' Competition Winners

    Superbugs Winners
  • UK Health System

    Sub Menu 16

    • Working with the NHS and other Healthcare Organisations
      • Collaborative Working
        • Collaborative Working Project between Lloyds Pharmacy and Pfizer Vaccines
        • Joint Working
      • Donations and Grants
        • Independent Medical Grants and Donations
        • Donations of Goods, Services and Benefit in Kind
        • Grants
        • Donations and Grants Enquiry Form
    • Working with Healthcare Professionals
      • FAQs: Working with Healthcare Professionals
      • Pharmacy
      • Healthcare Professionals Congress Sponsorship

    Sub Menu 17

    • Working with Patient Organisations
      • Patient Involvement in Research and Development
      • Our ongoing partnership with the UK Sepsis Trust
      • Partnering with the NIHR and young people on clinical research
    • Pfizer Healthcare Hub
      • Pfizer Healthcare Hub: 2018
      • Pfizer Healthcare Hub: 2017
      • Connect with the Hub
    Hot topic

    Osteoarthritis

    Osteoarthritis
  • News & Featured Stories
  • Media
  • Careers

    Carrers

    • Search Current Vacancies
    • Apprenticeships
      • Apprenticeship Vacancies
    • Undergraduate Placements
      • Undergraduate Vacancies
    • Meet our people
    • UK Top Employer
    • How Pfizer is fostering meaningful growth for every colleague, everywhere
  • Contact Us
  • Footer links

    Footer mobile menu

    • Footer Menu
    • Footer menu
      • Contact Us
      • Cookie Policy
      • Terms of Use
      • Privacy Policy
      • Sitemap
    • Footer social item
      • Facebook
      • Twitter
      • Instagram
      • YouTube

Our response to Channel 4 Dispatches

Our response to Channel 4 Dispatches
News & Featured Stories/ Our response to Channel 4 Dispatches
10/12/2021

Pfizer is disappointed to hear of the Channel 4 Dispatches documentary episode of 10th December 2021: “Vaccine Wars: Truth About Pfizer”.

The Dispatches documentary was being advertised before Pfizer itself was sent a list of areas to respond to with a very short window to reply.

We are concerned that unbalanced reporting will only serve to undermine the UK’s vaccination efforts at a time of much public concern. We have a number of concerns around specific accusations made in the approach to Pfizer, outlined below.
 



The estimated cost of making the vaccine

As the co-developer and manufacturer of the Pfizer-BioNTech COVID-19 mRNA Vaccine (BNT162b2), we can confirm the manufacturing estimate of 76p is grossly inaccurate and meaningless.

The true cost of bringing this mRNA vaccine to patients includes ongoing large scale clinical studies and pharmacovigilance, continued and increased manufacturing efforts including process improvements, and global distribution and supply which have clearly not been considered in the estimate the producers sought.

Likewise, to position this as a ‘charge’ to the NHS is not accurate; our COVID-19 vaccine has been centrally procured by the UK Government as part of the country's efforts to control the devastating impact of the pandemic.

Accusations on profiteering must be viewed within the scale of production we are witnessing. For the first time in living memory, humanity requires billions of vaccine doses at the same time and we are striving to deliver what we can, as fast as we can. We remain on track to produce 3 billion doses this year. To put that into context, Pfizer is one of the world’s largest vaccine manufacturers and prior to the pandemic, our annual output for all vaccines was 200 million doses per year. This is the biggest scale up in Pfizer’s history.

Pfizer-BioNTech have been transparent about the tiered pricing structure in place for high, middle, and low/lower-middle-income countries. High-income countries pay about the cost of a takeaway meal; low- and lower-middle-income countries pay a not-for-profit price.

 

Worldwide distribution of the vaccine

As of 29th November 2021, globally we have delivered 2.2 billion vaccines to 162 countries and territories in every region of the world. The companies have delivered more than 783 million doses to 94 low- and middle-income countries – more than double the number cited by the programme developers.

We have pledged to provide 2 billion doses of our COVID-19 vaccine to low/lower- and middle-income countries in 2021 and 2022, 1 billion doses each year. This is via multiple supply pathways including direct agreements, government donation programmes, humanitarian donation programmes and through an agreement with COVAX. It would be inaccurate to portray COVAX as the only route by which the vaccine reaches the poorest countries in the world.

We recognise and are concerned by the relative lower pace with which vaccines ended up reaching low-income countries. However, it is important to also acknowledge that approximately two thirds of the 1.3 billion people living in poverty are in the middle-income countries. Lower-middle-income and upper-middle-income countries are currently home to 75% of the world’s population and 62% of the world’s poor.
We have remained open about the challenges associated with managing this global vaccination effort.

Manufacturing this vaccine involves the use of over 280 materials, from 86 suppliers in 19 different countries. If any one of the 280 different components is not provided, we cannot manufacture or release the vaccine. With only two mRNA vaccines in the market, for the first time ever, there is not an abundance of known and experienced facilities in the world able to perform the critical steps needed to manufacture mRNA vaccines and the inputs to produce those vaccines at a large scale. To date, Pfizer and BioNTech have nine operational facilities supporting the COVID-19 vaccine global supply chain with two more joining this year as well as more than 20 contract manufacturers across four continents.

Distributing these types of products rapidly and at national scale has no precedent in modern public health, and close coordination across all stakeholders is critical for ensuring the success of vaccination campaigns. Holding manufacturers solely accountable on a supply number alone does not give an accurate account of vaccination reality. As we work to ensure equitable distribution, and countries become better prepared to receive, distribute, and administer the vaccine, we’ve seen the supply balance to weigh in favour of low/lower-middle income countries in the second half of 2021.
 

Misleading claims about rival vaccines

The production team has highlighted a presentation given in Canada which we believe has been wrongly attributed to Pfizer.

Following the authorisation in Canada of the Pfizer-BioNTech COVID-19 Vaccine (9th December, 2020), Pfizer received numerous requests from Canadian health professionals seeking support for education. To address this need, Pfizer provided funds to a third-party agency working with an external independent scientific committee to create an educational programme, independent of Pfizer. The speakers and presenters had complete editorial control of the content being presented. A third-party agency was engaged to develop and execute the programme, working with an external independent scientific committee. Reviewers of the programme were also independent from Pfizer. Pfizer did not provide presentation materials for this event and did not edit or influence the presentations. Some presenters and reviewers have acted as advisors to Pfizer in the past which, as per regulations in Canada, would have been disclosed by the speakers delivering the programme.

We refute any suggestion that Pfizer has sought to undermine others’ scientific endeavours. Our priority has always been getting high-quality, well-tolerated and effective vaccines to patients all over the world as quickly as possible and to help put an end to this deadly pandemic.

 


 

We are immensely proud of our colleagues across the globe who continue to show immense dedication, sacrifice, cooperation, and commitment to meet the unheard-of goal of producing billions of vaccine doses. Pfizer continues to invest in the COVID-19 programme including upgrades to the manufacturing process, continued research into alternative formulations of the existing vaccine and into variants of concern and the development of antiviral treatments, subject to regulatory approval.

A full and detailed response letter was shared with Channel 4; for any additional information, members of the media can contact the Press Office team.

Email: [email protected]

 

 

PP-CMR-GBR-0167 / December 2021

Related Hot Topics
What is a Variant
What is a Variant?
COVID-19 Vaccine Equity
Working To Reach Everyone, Everywhere
VacciNation report
VacciNation: tackling health inequalities across England
How Do Viruses Make Us Sick?
How Do Viruses Make Us Sick?
The Bodys Response to a Vaccine
A Life-Saving Education: The Body’s Response to a Vaccine
Vaccines partnerships
Vaccines partnerships addressing the diseases of today and tomorrow
Fighting the next public health crisis
Fighting the next public health crisis with vaccines
Osteoarthritis
Osteoarthritis: It’s time to talk about mental health
Tags
COVID-19

Footer

  • Contact Us
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Sitemap

Footer aside

  • Footer Aside
    • Facebook
    • Twitter
    • Instagram
    • YouTube

Copyright © 2017-2022 Pfizer Limited. PP-PFE-GBR-4248 / Nov 2021. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427